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Introduction: Mutations in the contactin-associated protein-like 2 (CNTNAP2) gene
(MIM#604569) encoding for CASPR2, a cell adhesion protein of the neurexin family, are
known to be associated with autism, intellectual disability, and other neuropsychiatric
disorders. A set of intronic deletions of CNTNAP2 gene has also been suggested to have
a causative role in individuals with a wide phenotypic spectrum, including Pitt-Hopkins
syndrome, cortical dysplasia–focal epilepsy syndrome, Tourette syndrome, language
dysfunction, and abnormal behavioral manifestations.
Case presentation: A 10-years-old boy was referred to the hospital withmild intellectual
disability and language impairment. Moreover, the child exhibited minor facial features,
epileptic seizures, and notable behavioral abnormalities including impulsivity, aggressivity,
and hyperactivity suggestive of the diagnosis of disruptive, impulse-control and conduct
disorder (CD). Array comparative genomic hybridization (CGH) revealed a copy number
variant (CNV) deletion in the first intron of CNTNAP2 gene inherited from a healthy father.
Conclusions: A comprehensive description of the phenotypic features of the child is
provided, revealing a distinct and remarkable alteration of social behavior not previously
reported in individuals affected by disorders related to CNTNAP2 gene disruptions. A
possible causative link between the deletion of a non-coding regulatory region and the
symptoms presented by the boy has been advanced.
Keywords:CNTNAP2 gene, intronic copy number variant, conduct disorder (CD), epilepsy, intellectual disability (ID)
INTRODUCTION
Anew strong candidate gene for psychiatric and language disorders is contactin-associated protein-
like 2 (CNTNAP2) gene (MIM#604569).CNTNAP2 is a member of the neurexin family and consists
of a transcript of 24 exons encoding for CASPR2 protein, which functions as a cell-adhesion
molecule in many neuronal activities, such as neuronal migration, dendritic arborization, and
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synaptic transmission. The main role of CASPR2 is the
conduction of axon potentials and the clustering of voltage-
gated potassium channels at the juxtaparanodes in both
myelinated axons of the spinal cord and of the central nervous
system (1, 2). However, the high expression of the protein
in Broca’s area and other perisylvian regions is consistent
with the emerging role in normal language development and
social communication (3, 4). By its size, spanning 2.3Mb at
chromosomal region 7q35-36, CNTNAP2 is a target for a wide
variety of mutations and structural rearrangements, including
copy number variants (CNVs). Some intronic CNV deletions
of CNTNAP2 gene have been reported in individuals with Pitt-
Hopkins syndrome (PTHS) and cortical dysplasia–focal epilepsy
syndrome (CDFES), epilepsy with auditory features (EAF),
autism spectrum disorder (ASD) and intellectual disability (ID),
speech impairment, Tourette syndrome (TS), and abnormal
behavioral manifestations (5–9). Interestingly, variants found in
the first intronic region of CNTNAP2 have been shown to lead
to the loss of critical regulatory elements of some conserved
transcription factor (TF) binding sites (TFBSs) involved in
language and social-emotional development.
Here, we report a child presenting with neuropsychiatric
disturbances including notable behavioral disorders consisting of
frequent and severe outbursts of impulsivity, aggressivity, and
hyperactivity suggestive of the diagnosis of “disruptive, impulse-
control, and conduct disorder (CD)” and TS. Moreover, the child
exhibited minor facial features, mild ID, language impairment,
and epileptic seizures. Molecular investigation carried out by
array comparative genomic hybridization (aCGH) revealed a
CNV deletion spanning 95.4 kb in intron 1 of CNTNAP2 gene
inherited from a healthy father. A possible causative link between
the deletion of a non-coding regulatory region and the clinical
manifestations observed in the boy has been raised.
MATERIALS AND METHODS
Case Presentation
A 10-years-old boy is the second child of healthy unrelated
Italian parents. Both older half-siblings, an 18-years-old boy born
from the father’s previous marriage and a 16-years-old sister are
healthy. In the paternal line, there is a history of family members
affected by polyposis intestinalis with early deaths.
At gestation, themother was 34 years old and the father was 40
years old. The mother denied having had complications during
the gestation and reported normal fetal movements. Intrauterine
ultrasound did not show fetal anomalies. The child was born at 40
weeks of gestation by cesarean section as in the previous delivery.
Birth weight was 3.6 kg, length 51 cm, and head circumference
35 cm (all within normal limits). The Apgar scores were eight at
Abbreviations: aCGH, array comparative genome hybridization; ASD, autism
spectrum disorder; CCD, CASPR2-deficiency disorder; CD, conduct disorder;
CNTNAP2, contactin-associated protein-like 2; CNV, copy number variant;
CDFES, cortical dysplasia–focal epilepsy syndrome; EAFs, epilepsy and auditory
features; EDG, esophagogastroduodenoscopy; ESR1, estrogen receptor alpha gene;
FOXP1, forkhead box P1; FOXP2, forkhead box P2; ID, intellectual disability;
OCD, obsessive–compulsive disorder; PTHS, Pitt-Hopkins syndrome; STOX1A,
storkhead box 1A; TFBS, transcription factor binding site; TF, transcription factor;
TCF4, transcription factor 4; TS, Tourette syndrome.
one and 10 at 5min. At birth, neither clinical signs nor notable
facial features were noticed, and the child was discharged by the
hospital in good condition.
During the 1st months, he exhibited normal motor
development but had speech delay, which started at the age
of 28 months with the pronunciation of a single word. At the
age of 3 years, the parents noted that the child was extremely
overactive with mood swings and difficulty in sleeping. The
anomalous behavior became progressively more evident, and
at the age of 4 years, he was remarkably aggressive. At the
age of 5 years, he was hospitalized in North Italy due to
developmental delay, frequent insomnia episodes, stereotypic
movements (lateral swinging), and phonologic disturbances.
During hospitalization in that center, routine examination
including thyroid markers, ECG, and brain MRI were performed
with normal results. In the Leiter-R test (non-verbal cognitive
capacity), brief IQ of 85 was registered, and the “Child Behavioral
Check List” (CBCL) showed affective impairment, anxiety,
hyperactivity, and obsessive behavior. The child was discharged
with the diagnosis of behavioral disturbance with hyperactivity,
phonologic disturbances, and EEG alterations. At the age of 8
and 9 years, right-sided focal tonic seizures lasting a few minutes
were recorded. Treatment with valproate at 20 mg/kg/day
was started with good drug response. During the subsequent
years, he was followed up as an outpatient at the Pediatric
Unit and Pediatric Emergency Unit, University Hospital
“Policlinico-Vittorio Emanuele,” Catania, Italy, since he showed
mild speech impairment and episodes of aggressivity against
parents, teachers, and peers. In one of these episodes, he caused
FIGURE 1 | Photo showing a 10-years-old boy with sparse eyebrows, short
nose, long flat philtrum and thin lips.
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FIGURE 2 | EEG during sleep showing spike and wave discharges in fronto-centro-temporal region.
injury to one of his teachers. Risperidone 1 mg/day was started
but irregularly administered with poor results. At the age of 10
years, he was admitted to this institution for a clinical workup.
His weight was 51 kg (>90th percentile), length 143 cm (75th
percentile), and head circumference 55 cm (90th percentile). On
physical examination, minor feature anomalies were noticed
and consisted of upslanting palpebral fissures, sparse eyebrows,
short nose, flat philtrum, thin lips, and wide earlobes (Figure 1).
Hands and feet were short. The heart, thorax, abdomen, and
internal organs were normal. Neurological examination was
normal, and patellar tendon reflexes were normally elicited.
EEG during wakefulness and during sleep showed spike and
wave discharges in the fronto-centro-temporal region, and
during eye opening, photic stimulation and hyperventilation
was unchanged (Figure 2). A fundus examination and hearing
exploration were normal. At the age of 10 years, brief IQ was 85.
No more seizures were reported, and treatment with valproate
was withdrawn. Due to the frequent chronic episodes of diarrhea
and familiar history of polyposis intestinalis, an abdominal
ultrasound exam and esophagogastroduodenoscopy (EDG) were
performed, and tissue samples were examined. The EDG did
not show anomalies, and the macroscopic sample analysis of the
duodenal tissue was normal. The neuropsychiatric evaluation
of the child displayed several dysfunctions. His cognitive and
behavioral profile consisted of a mild ID and high score of
generalized anxiety and depression with intrusive thoughts.
Complex, chronic motor tics were seen in the child in association
with signs of obsessive–compulsive disorder (TS). Self-esteem
and social relation result compromised. Verbal and physical
aggressivity and impulsivity were particularly expressed. The
final psychiatric diagnosis was disruptive, impulse-control and
CD. The results of the neuropsychiatric evaluation of proband
and parents are reported in Table 1(A–J). At last examination,
at 11 years old, seizures were not reported, while behavioral
impairments were unmodified.
Microarray Experiment and Data Analysis
Genomic DNA was isolated from peripheral blood of the
proband, together with the proband’s mother and father.
aCGH was performed by CytoSure ISCA 8 × 60 k array from
Oxford Gene Technology (OGT) according to the manufacturer’s
recommendations (Agilent Technologies, Santa Clara, CA).
aCGH data were analyzed and interpreted using Cytosure
software (GRCh38 assembly) provided by OGT.
Aiming at exploring and better interpreting the
phenotype linked with the proband’s CNV, we used
the publicly available patient data on the Database of
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TABLE 1 | (A–J). Neuropsychological assessment of proband (A–G) and both parents (H–J).
A. WISC-IV (Wechsler Intelligence Scale for Children) B. CY-BOSH (Children’s Yale–Brown Obsessive–Compulsive Scale)
Verbal comprehension 70 Subtotal Obsessions 8
Perceptual reasoning 71 Subtotal Compulsions 16
Working memory 64 Total 24 (low score)
Processing speed 88 C. General Score anxiety disorders
Standard score range for WISC-IV: 64 Total 19 points T 66 (low score)
D. MASC (Multidimensional Anxiety Scale for Children) test
Physical symptoms Total 19 Points T 63 (borderline)
Harm avoidance Total 20 Points T 57 (normal)
Social anxiety Total 18 Points T 65 (low score)
Separation/Panic Total 20 Points T 82 (low score)
Total Total 77 Points T 72 (positive)
E. Children’s Depression Inventory (CDI)
Cutoff 15
Total 24 (low score)
F. Small bell Test (measure selective and sustained attention)
Speed Total 25 (between 50 and 75th percentile)
Accuracy Total 57 (25th percentile)
G. Paper and Pencil test
Insecure child with decreased auto-esteem and social relation
H. CBCL (Child Behavior Checklist)
Interview to the father Interview to the mother
Total Score pT 73 low score pT 63 (borderline)
Internalizing problems pT 71 low score pT 64
Externalizing problems pT 74 low score pT 66
Thought problem Scale pT 79 pT 67
Aggressive behavior Scale pT 76 pT 63
Anxiety-Depression pT 74 pT 66
I. SNAP-IV (Swanson, Nolan and Pelham-IV)
Interview to the father Cutoff Interview to the mother Cutoff
Inattention Total 15 –> 1,66 1,78 Total 12 –> 1,33 1,78
Hyperactivity/Impulsivity Total 17 –> 1,88 1,44 Total 14 –> 1,55 1.44
Oppositional defiant Total 15 –> 1,87 1,88 Total 10 –> 1,25 1,88
J. SCOD IV (Rating scale for disruptive behavioral subscale)
Interview to the father Interview to the mother
Inattention Percentile 95–100 Percentile 95–100
Defiant disorder Percentile 95–100 Percentile 95–100
Conduct disorder Percentile 95–100 Percentile 95–100
Genomic Variants (DGV) (dgv.tcag.ca), DECIPHER web-
based resource (decipher.sanger.ac.uk), CNV dataset from
Clinical Genome Resource (ClinGen), and Morbidity Map of
Developmental Delay displayed at UCSC Genome Browser
(genome.ucsc.edu).
The molecular karyotype revealed that the proband carries
a CNV deletion of 95.4 kb in 7q35(146,271,924-146,367,324)x1
inherited from the healthy father. The microdeletion detected
in the first intronic region of the CNTNAP2 gene has been
previously reported in the DGV database.
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DISCUSSION
The young boy presented with minor facial dysmorphism, mild
ID, speech impairment, sleep disorders, and severe behavioral
disturbances and TS. Two episodes of partial epileptic seizures
were also recorded. Behavioral disturbances were impressive,
and the child exhibited frequent and severe outbursts of
aggressivity, impulsivity, and hyperactivity, which led to the
diagnosis of disruptive, impulse-control and CD. Much of the
clinical signs presented in the child have been also reported
in patients affected by CASPR2-deficiency disorder (CDD)
associated with language impairment, notable impaired behavior
and CD, TS, epileptic seizures, moderate ID, and poor social
interactions (8, 10, 11). aCGH analysis revealed a small CNV
deletion in intron 1 of CNTNAP2 gene inherited from the
unaffected father. The incomplete penetrance of the CNV
variant may not exclude the pathogenic link between the
microdeletion and disruption of gene-regulatory and protein
interactions underlying some neural and behavioral pathways
involved in learning ability and language and social behaviors
(11–13). Deletions with similar size (e.g., essv12997739) of
the variant in question have been reported in population,
but their pathogenicity and phenotypic contribution are still
uncertain. A wide variety of intronic variants of CNTNAP2
gene has been reported in patients with severe ID, autistic
behavior, epilepsy, and breathing anomalies that phenotypically
overlap with PTHS (14, 15). Additional reports have also been
found in individuals with epilepsy (16), EAF (7), epilepsy,
and schizophrenia in three non-related Caucasian patients (17).
Moreover, Strauss et al. (18) reported children with cortical
dysplasia, focal epilepsy, relative macrocephaly, and diminished
deep-tendon reflexes in association with language regression,
hyperactivity, and impulsive and aggressive behavior. Speech
disorders, behavioral disturbances, and other neuropsychiatric
disorders have been identified in patients with alterations in the
CNTNAP2 gene (12, 19–22). Verkerk et al. (23) described a family
with members affected by TS and obsessive–compulsive disorder
(OCD), in which mutations in CNTNAP2 gene expression have
been found to alter the distribution of the K(+) channels
in the nervous system with abnormal conduction and/or
repolarization of active potential, leading to cause anomalous
motor movements observed in individuals affected by TS. In
contrast with this finding, no individuals with clinical evidence
of TS have been reported by Belloso et al. (24) in a family
with a balanced reciprocal translocation (t7;15)(q35:q26.1). The
first intron of CNTNAP2 is known to be a susceptible locus
for structural rearrangements that may influence the genetic
modulation of the gene since it contains some conserved
regulatory regions implicated in the transcriptional network
of neurodevelopmental processes regulating language skills and
social-emotional functioning. Some studies have experimentally
identified consensus binding sequences for a selected set of TFs,
such as STOX1A (8), TCF4 (25), FOXP1, and FOXP2 (26, 27),
which can influence the transcriptional control of the gene
and interact with CNTNAP2 to co-regulate the developmental
pathways of human speech and social behavior.
Limitations
Our study has some limitations. First is that the described CNV
may be a combined effect of additional rare variants, which are
not excluded in the present case, and should be investigated by
whole-exome sequencing (WES). Secondly, with regard to the
quantitative PCR validation, CNTNAP2 gene dosage variation
was not included. However, we neglected to correlate the effect
of CNV loss with the gene expression level to examine alterations
in mRNA synthesis and the activity of Caspr2 protein. The
impact of the intronic deletion in the transcriptional regulatory
network of CNTNAP2 that correlated with the analysis of
FOXP interactome warrants additional investigations. Our study
might serve as a first step to identify a non-coding regulatory
variant enriched for potentially important TFs implicated in
neurodevelopment. We believe that it would be important to
determine whether (i) the effect of CNV loss may affect variations
in the CNTNAP2-encoded CASPR2 protein (e.g., splice site
mutations, posttranslational modifications) and whether (ii) the
clinical phenotype may depend on the association between
CNV loss and DNA methylation pattern of gene promoter and
intron 1.
CONCLUDING REMARKS
The present study deems that regardless of sufficient evidence
to conclude that the intronic deletion of CNTNAP2 has a
potential contribution in the diagnosis, there are some findings
for believing in a likely positive correlation between the clinical
presentation of the child and individuals affected by CDD.
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